Pfizer Inc (NYSE: PFE) is a pharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, vaccines, and biopharmaceutical products. Revenue is generated through direct product sales to wholesalers, hospitals, pharmacies, and government purchasers, supplemented by alliance revenues from collaboration and co-promotion agreements with external partners. Pfizer operates internationally, with subsidiaries outside the U.S. reporting on a fiscal year ended November 30 and U.S. subsidiaries on a calendar year ended December 31. The company's portfolio spans multiple therapeutic areas, with commercial operations, a research and development pipeline, and intellectual property protections through patents cited as core business elements in the FY2025 10-K filed February 26, 2026. Pfizer faces competition across its product categories and operates under government regulation and pricing constraints, including the 340B Drug Pricing Program, as disclosed in the same filing.

Revenue model

Product sales to wholesalers, hospitals, pharmacies, and government purchasers; alliance and co-promotion revenues from collaboration agreements with third-party partners.

Products and services

Prescription medicines, vaccines, and biopharmaceutical products across multiple therapeutic areas. Specific product names and segment revenue breakdowns are not supported by the available filing excerpts.

Customers and end markets

Hospitals, pharmacies, wholesalers, managed care organizations, and government purchasers including participants in the 340B Drug Pricing Program. End markets include retail and institutional healthcare channels in the U.S. and internationally.

Value-chain role

Vertically integrated pharmaceutical manufacturer and commercializer: research and development, manufacturing, sales, and marketing of branded prescription drugs and vaccines.

Geographic exposure

Operations in the U.S. and international markets. International subsidiaries report on a fiscal year ending November 30; U.S. subsidiaries report on a calendar year ending December 31, per the FY2025 10-K.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Bristol-Myers Squibb Co Catalent, Inc. Eli Lilly and Co Johnson & Johnson Merck & Co Inc Organon & Co Royalty Pharma PLC Viatris Inc Zoetis Inc